Gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life cross-sectional study

Background and objectivesHematopoietic stem cell transplantation (HCT) is a treatment for hematopoietic diseases. However, most cured female patients may suffer from premature ovarian insufficiency (POI) after HCT, which is mainly caused by the pre-HCT conditioning regimen. Hence, this study aims to explore the impact of HCT treatment on reproductive and ovarian functions in female survivors. MethodsA total of 55 female participants under the age of 40, who underwent HCT and met the inclusion criteria were enrolled. Data related to blood disease, menstruation, and fertility in the 3 years following HCT were collected. ResultsThe involved patients received transplantation at different age stages, ranging from 8 to 37. All patients, except those with aplastic anemia (AA; 5/55), received a myeloablative conditioning regimen, usually modified total body irradiation/cyclophosphamide (TBI/Cy; 25/55) or modified Busulfan/cyclophosphamide (Bu/Cy; 23/55). Among women (42/55) who menstruated before HCT, 16.67% (7/42) had a spontaneous menstrual relapse and 83.3% (35/42) had amenorrhea after HCT. 72.7% (40/55) could be regarded as having POI. This proportion included 100% (25/25) of women aged 21-40 at the time of HCT, 62.5% (15/24) of those aged 11-20, and 0% (0/6) of those <= 10 years old. Patients with AML were more likely to have POI (95.7%). Patients aged <= 10 years (0%) or 11-20 years (16.7%) at the time of HCT were less likely to have moderate to severe menopause than those 21-40 years old (44%). ConclusionThe prevalence of POI following HCT was high and POI was associated with age, conditioning regimen, and type of blood disease.

Automated summary

This study found that HCT treatment may result in female patients developing POI, which is associated with age, conditioning regimen, and type of blood disease.